Modulation of the immune system has emerged as a key strategy in novel cancer therapies, demonstrating potential across various cancer types [16, 17, 18], including the recent exploitation ofTLR‐like receptors (TLR7, TLR8) and STING. The gene discussed is STING1; the disease is cancer.